225 related articles for article (PubMed ID: 30617137)
1. Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter?
Ben-Aharon I; Elkabets M; Pelossof R; Yu KH; Iacubuzio-Donahue CA; Leach SD; Lowery MA; Goodman KA; O'Reilly EM
Clin Cancer Res; 2019 Apr; 25(7):2185-2193. PubMed ID: 30617137
[TBL] [Abstract][Full Text] [Related]
2. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
Tsang ES; Topham JT; Karasinska JM; Lee MKC; Williamson LM; Mendis S; Denroche RE; Jang GH; Kalloger SE; Moore RA; Mungall AJ; Bathe OF; Tang PA; Notta F; Wilson JM; Laskin J; O'Kane GM; Knox JJ; Goodwin RA; Loree JM; Jones SJM; Marra MA; Gallinger S; Schaeffer DF; Renouf DJ
Clin Cancer Res; 2021 Jan; 27(1):246-254. PubMed ID: 32958704
[TBL] [Abstract][Full Text] [Related]
3. Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms.
Peran I; Madhavan S; Byers SW; McCoy MD
Clin Cancer Res; 2018 Aug; 24(16):3813-3819. PubMed ID: 29739787
[No Abstract] [Full Text] [Related]
4. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
5. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.
Bannon SA; Montiel MF; Goldstein JB; Dong W; Mork ME; Borras E; Hasanov M; Varadhachary GR; Maitra A; Katz MH; Feng L; Futreal A; Fogelman DR; Vilar E; McAllister F
Cancer Prev Res (Phila); 2018 Nov; 11(11):679-686. PubMed ID: 30274973
[No Abstract] [Full Text] [Related]
6. Demographic, clinical, and pathological features of early onset pancreatic cancer patients.
Ntala C; Debernardi S; Feakins RM; Crnogorac-Jurcevic T
BMC Gastroenterol; 2018 Sep; 18(1):139. PubMed ID: 30208959
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer.
Wang OH; Azizian N; Guo M; Capello M; Deng D; Zang F; Fry J; Katz MH; Fleming JB; Lee JE; Wolff RA; Hanash S; Wang H; Maitra A
PLoS One; 2016; 11(3):e0152300. PubMed ID: 27023625
[TBL] [Abstract][Full Text] [Related]
8. Integrative analysis of gene expression profiles reveals specific signaling pathways associated with pancreatic duct adenocarcinoma.
Li J; Tan W; Peng L; Zhang J; Huang X; Cui Q; Zheng J; Tan W; Wu C; Lin D
Cancer Commun (Lond); 2018 Apr; 38(1):13. PubMed ID: 29764514
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic adenocarcinomas with mature blood vessels have better overall survival.
Katsuta E; Qi Q; Peng X; Hochwald SN; Yan L; Takabe K
Sci Rep; 2019 Feb; 9(1):1310. PubMed ID: 30718678
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
11. Integrated Genomic Analysis of Pancreatic Ductal Adenocarcinomas Reveals Genomic Rearrangement Events as Significant Drivers of Disease.
Murphy SJ; Hart SN; Halling GC; Johnson SH; Smadbeck JB; Drucker T; Lima JF; Rohakhtar FR; Harris FR; Kosari F; Subramanian S; Petersen GM; Wiltshire TD; Kipp BR; Truty MJ; McWilliams RR; Couch FJ; Vasmatzis G
Cancer Res; 2016 Feb; 76(3):749-61. PubMed ID: 26676757
[TBL] [Abstract][Full Text] [Related]
12. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
13. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
[No Abstract] [Full Text] [Related]
14. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
15. Early-onset pancreatic cancer: a population-based study using the SEER registry.
Ansari D; Althini C; Ohlsson H; Andersson R
Langenbecks Arch Surg; 2019 Aug; 404(5):565-571. PubMed ID: 31377855
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
17. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
18. Association of prion protein expression with pancreatic adenocarcinoma survival in the SEER residual tissue repository.
Sy MS; Altekruse SF; Li C; Lynch CF; Goodman MT; Hernandez BY; Zhou L; Saber MS; Hewitt SM; Xin W
Cancer Biomark; 2011-2012; 10(6):251-8. PubMed ID: 22820080
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
[TBL] [Abstract][Full Text] [Related]
20. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
